Limits...
Complete response to FOLFOX4 therapy in a patient with advanced urothelial cancer: a case report.

Seo YR, Kim SH, Kim HJ, Kim CK, Park SK, Koh ES, Hong DS - J Hematol Oncol (2010)

Bottom Line: However, he had new liver, lung metastases and synchronous two separate primary colon cancer.The lung metastasis lesion was confirmed as a metastatic urothelial cancer via percutaneous transthoracic needle biopsy (PTNB).The patient was still showing a complete response after 4 months.

View Article: PubMed Central - HTML - PubMed

Affiliation: Division of Hematology & Oncology, Department of Internal Medicine Soonchunhyang University College of Medicine, Bucheon, Korea.

ABSTRACT
No standard has been established for salvage therapy in gemcitabine refractory advanced urothelial cancer. We report the complete response to FOLFOX4 therapy of a metastatic urothelial cancer patient, for whom adjuvant gemcitabine plus cisplatin combination chemotherapy had failed. A 54-year-old male patient with urothelial cancer (transitional cell carcinoma) in the right kidney underwent three rounds of adjuvant gemcitabine-cisplatin chemotherapy after extensive radical nephrectomy. However, he had new liver, lung metastases and synchronous two separate primary colon cancer. The lung metastasis lesion was confirmed as a metastatic urothelial cancer via percutaneous transthoracic needle biopsy (PTNB). Liver and lung metastasis lesions disappeared after the 4th cycle of FOLFOX4 chemotherapy. In addition, colon cancer also disappeared after the 8th cycle of FOLFOX4 chemotherapy. The patient was still showing a complete response after 4 months. Clinical trials using the FOLFOX regimen as salvage therapy for gemcitabine-refractory advanced urothelial cancer are warranted.

Show MeSH

Related in: MedlinePlus

A: The pelvocalyceal tumor of the kidney reveals high-grade urothelial carcinoma (H&E, ×100). B: PTNB from lung shows metastatic urothelial carcinoma (H&E, ×200).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2818621&req=5

Figure 1: A: The pelvocalyceal tumor of the kidney reveals high-grade urothelial carcinoma (H&E, ×100). B: PTNB from lung shows metastatic urothelial carcinoma (H&E, ×200).

Mentions: A 54-year-old male with urothelial cancer (transitional cell carcinoma) was transferred to the hemato-oncology department after the discovery of lung metastases. Three months previously, he had undergone a radical nephrectomy and hilar lymphadenectomy for a left kidney mass, which was identified as invasive papillary urothelial carcinoma, extending to the renal parenchyma. The resection margin was free from carcinoma, although there was metastatic carcinoma in one out of two lymph nodes (pT3N3 M0) (Figure 1A). No metastatic lesion was found on chest computed tomography (CT) or on abdomen CT before surgery. Postoperatively, he underwent three rounds of adjuvant chemotherapy with gemcitabine (1000 mg/m2 D1, 8, 15) and cisplatin (75 mg/m2 D1).


Complete response to FOLFOX4 therapy in a patient with advanced urothelial cancer: a case report.

Seo YR, Kim SH, Kim HJ, Kim CK, Park SK, Koh ES, Hong DS - J Hematol Oncol (2010)

A: The pelvocalyceal tumor of the kidney reveals high-grade urothelial carcinoma (H&E, ×100). B: PTNB from lung shows metastatic urothelial carcinoma (H&E, ×200).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2818621&req=5

Figure 1: A: The pelvocalyceal tumor of the kidney reveals high-grade urothelial carcinoma (H&E, ×100). B: PTNB from lung shows metastatic urothelial carcinoma (H&E, ×200).
Mentions: A 54-year-old male with urothelial cancer (transitional cell carcinoma) was transferred to the hemato-oncology department after the discovery of lung metastases. Three months previously, he had undergone a radical nephrectomy and hilar lymphadenectomy for a left kidney mass, which was identified as invasive papillary urothelial carcinoma, extending to the renal parenchyma. The resection margin was free from carcinoma, although there was metastatic carcinoma in one out of two lymph nodes (pT3N3 M0) (Figure 1A). No metastatic lesion was found on chest computed tomography (CT) or on abdomen CT before surgery. Postoperatively, he underwent three rounds of adjuvant chemotherapy with gemcitabine (1000 mg/m2 D1, 8, 15) and cisplatin (75 mg/m2 D1).

Bottom Line: However, he had new liver, lung metastases and synchronous two separate primary colon cancer.The lung metastasis lesion was confirmed as a metastatic urothelial cancer via percutaneous transthoracic needle biopsy (PTNB).The patient was still showing a complete response after 4 months.

View Article: PubMed Central - HTML - PubMed

Affiliation: Division of Hematology & Oncology, Department of Internal Medicine Soonchunhyang University College of Medicine, Bucheon, Korea.

ABSTRACT
No standard has been established for salvage therapy in gemcitabine refractory advanced urothelial cancer. We report the complete response to FOLFOX4 therapy of a metastatic urothelial cancer patient, for whom adjuvant gemcitabine plus cisplatin combination chemotherapy had failed. A 54-year-old male patient with urothelial cancer (transitional cell carcinoma) in the right kidney underwent three rounds of adjuvant gemcitabine-cisplatin chemotherapy after extensive radical nephrectomy. However, he had new liver, lung metastases and synchronous two separate primary colon cancer. The lung metastasis lesion was confirmed as a metastatic urothelial cancer via percutaneous transthoracic needle biopsy (PTNB). Liver and lung metastasis lesions disappeared after the 4th cycle of FOLFOX4 chemotherapy. In addition, colon cancer also disappeared after the 8th cycle of FOLFOX4 chemotherapy. The patient was still showing a complete response after 4 months. Clinical trials using the FOLFOX regimen as salvage therapy for gemcitabine-refractory advanced urothelial cancer are warranted.

Show MeSH
Related in: MedlinePlus